{
  "id": 19175638,
  "title": "#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky",
  "url": "https://urgent.news/2026/11/09/aha26-boehringer-to-seek-approval-of-obesity-shot-but-gaining-market",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T15:58:37.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/aha26-boehringer-to-seek-approval-of-obesity-shot-but-gaining-market-share-could-be-tricky/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like heart attacks and strokes. If the ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}